HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice

doi:10.3748/wjg.v22.i26.5879

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11391)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

799

WORD

342

HTML

6310

Figures (1-2)

334

Sum=7785

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

342

Download

416

Sum=758

Publishing Process of This Article

Item

Count

Browse

1106

Download

1742

Sum=2848

Jul 14, 2016 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (97)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jul 14, 2016; 22(26): 5879-5887
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.5879

Full Size Figure Download Figure

Figure 1 Diagnostic algorithm for HER2 status evaluation in gastric and gastroesophageal adenocarcinomas. Immunohistochemistry (IHC) represents the initial testing method. IHC score 0 and 1+ are considered negative while score 3+ cases are considered positive and do not need further testing. Fluorescence in situ hybridization testing is required only for equivocal IHC score 2+ cases. On the basis of HER2 (red spots): CEP 17 (green spots) ratio (< 2 vs≥ 2) patients are eligible or not to anti-HER2 therapy.

Citation: Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 2016; 22(26): 5879-5887
URL: https://www.wjgnet.com/1007-9327/full/v22/i26/5879.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i26.5879